- Home
- SKX vs EXEL Comparison
SKX vs EXEL Comparison
Compare SKX & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKX
- EXEL
- Stock Information
- Founded
- SKX 1992
- EXEL 1994
- Country
- SKX United States
- EXEL United States
- Employees
- SKX N/A
- EXEL 1310
- Industry
- SKX Shoe Manufacturing
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SKX Consumer Discretionary
- EXEL Health Care
- Exchange
- SKX Nasdaq
- EXEL Nasdaq
- Market Cap
- SKX 10.4B
- EXEL 10.4B
- IPO Year
- SKX 1999
- EXEL 2000
- Fundamental
- Price
- SKX $73.80
- EXEL $36.43
- Analyst Decision
- SKX Buy
- EXEL Buy
- Analyst Count
- SKX 12
- EXEL 17
- Target Price
- SKX $78.00
- EXEL $35.50
- AVG Volume (30 Days)
- SKX 1.7M
- EXEL 2.4M
- Earning Date
- SKX 02-06-2025
- EXEL 02-04-2025
- Dividend Yield
- SKX N/A
- EXEL N/A
- EPS Growth
- SKX 18.90
- EXEL 441.02
- EPS
- SKX 4.05
- EXEL 1.55
- Revenue
- SKX $8,717,875,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- SKX $13.31
- EXEL $20.53
- Revenue Next Year
- SKX $10.23
- EXEL $0.95
- P/E Ratio
- SKX $18.10
- EXEL $23.54
- Revenue Growth
- SKX 10.10
- EXEL 17.31
- 52 Week Low
- SKX $55.67
- EXEL $20.02
- 52 Week High
- SKX $75.09
- EXEL $37.59
- Technical
- Relative Strength Index (RSI)
- SKX 69.09
- EXEL 59.74
- Support Level
- SKX $68.68
- EXEL $33.05
- Resistance Level
- SKX $73.20
- EXEL $37.59
- Average True Range (ATR)
- SKX 1.99
- EXEL 1.02
- MACD
- SKX 0.20
- EXEL 0.26
- Stochastic Oscillator
- SKX 99.87
- EXEL 74.45
About SKX Skechers U.S.A. Inc.
Skechers USA Inc is a lifestyle footwear company under the Skechers GO brand name. Products offered include various styles of women's shoes, men's shoes, girl's shoes, boy's shoes, performance shoes, and work shoes. Allied products offered are apparel, bags, eyewear, toys, and more. Its products are available for sale at department and specialty stores, athletic and independent retailers, boutiques, and internet retailers. The company's operating segments includes Wholesale and Direct-to-Consumer. It generates maximum revenue from the Wholesale segment.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.